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Multiple sclerosis (MS) is common in Europe affecting up to 1:500 people. In an effort to identify genes influencing susceptibility
to the disease, we have performed a population-based whole genome screen for association. In this study, 6000 microsatellite markers
were typed in separately pooled DNA samples from MS patients (n = 188) and matched controls (n = 188). Interpretable data was
obtained from 4661 of these markers. Refining analysis of the most promising markers identified 10 showing potential evidence for
association.
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1. Introduction aetiology of MS has been established by classical epidemi-Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system with a
wide range of clinical manifestations, which most common-
ly presents in the third or fourth decade. There are no
published studies of prevalence from Portugal but a rate
of 15 per 100,000 was observed by Callegaro et al. (2001) in
Sao Paulo, Brazil amongst a population of mainly Portu-
guese descent. The importance of genetic factors in the0165-5728/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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1 Both authors contributed equally to this work.ological studies such as those showing a higher concordance
rate for MS in monozygotic (25%) compared with dizygotic
twins (3%) (Ebers et al., 1996). Efforts to identify suscep-
tibility genes have established association of the disease
with MHC Class II alleles (Marrosu et al., 1988; Olerup and
Hillert, 1991), but no other consistently supported genes
have thus far been identified (reviewed in Compston et al.,
1998).
For diseases not following simple Mendelian inheritance,
such as MS, the absence of multigenerational families
effectively precludes the use of parametric linkage analysis,
at the same time non-parametric linkage analysis lacks
power when the genetic effects attributable to individual
loci are modest. In this setting, tests for association are
optimal (Risch and Merikangas, 1996). The goal of popu-
M. Santos et al. / Journal of Neuroimlation-based association studies is to identify genetic var-
iants that differ in frequency between (unrelated) affected
individuals and healthy controls (Kruglyak, 1999). This
difference in frequency of a marker allele may reflect a
direct causative effect of the allele in question, or may occur
when the marker allele is in linkage disequilibrium (LD)
with the biologically relevant genetic variant.
In order to screen the genome for LD in the Portuguese
MS population, we have analysed a dense map of micro-
satellites markers in a case-control cohort using DNA
pooling for efficiency (Barcellos et al., 1997; Sawcer et
al., 2002).Table 1
Empirical p-values for the most extreme 10 markers
Marker p-value
D10S1423 0.0085
D11S1333 0.0013
D11S1914 0.0034
D11S4046 0.0022
D4S2921a 0.0078
D4S426a 0.0052
D5S1464 0.0027
D6S2444 0.0038
TNFa 0.0015
D7S630 0.0062
a These two markers were not included in the 529 considered by Yeo
et al.2. Material and methods
2.1. Patients
We studied a sample of 188 unrelated patients (129
females: 59 males) with an average age of 37 (17–64)
years. All were of Portuguese origin and all had a definite
diagnosis of MS, according to the criteria of Poser et al.
(1983). We also studied 188 unrelated healthy controls
(HC), matched by sex, age (F 2 years) and region of origin.
All the participants were informed about the purposes of this
study and gave written consent to genetic analysis.
2.2. DNA pooling
Genomic DNA from all subjects was isolated from
peripheral blood, using a genomic DNA isolation kit (Pure-
gene). DNA concentration from stocks was measured twice
in a BECKMAN DU 650 spectrophotometer, and all sam-
ples were diluted to a final concentration of 60 ng/Al. DNA
concentration of these dilutions was then measured with the
PicoGreen system (Molecular Probes), according to the
manufacturer’s instructions, and again diluted to a final
concentration of 25 ng/Al.
We used 100 Al (2.5 Ag) of each sample, and pooled the
188 cases and 188 controls, separately.
2.3. Polymerase chain reaction and capillary
electrophoresis
The GAMES collaborative provided the 6000 markers,
which were analysed in the case and control pools. DNA
from the two pools was amplified twice for each marker, in
a final reaction volume of 15 Al using True Allelek Premix
(Applied Biosystems), according to manufacturer’s instruc-
tions. Each set of PCR products was then electrophoresed
twice, on a 3700 DNA analyser (Applied Biosystems).
Semi-automated sizing was performed using the GENES-
CAN software (Applied Biosystems); 4661 markers pro-
vided electropherograms of sufficient quality to enable
semi-automated analysis using the Applied Biosystems
GENOTYPER (version 3.6) software.2.4. Statistical analysis
Genotyping a microsatellite in a pooled DNA sample
generates an allele image pattern (AIP) consisting of a series
of fragments, the signal from each reflecting the frequency
of the corresponding allele. For each marker, a weighted
average AIP was calculated for each pool, using the avail-
able data from that pool (up to four AIPs for each). The peak
height distribution thus generated was then normalised
according to the number of alleles in the corresponding
pool. The resulting allele count distributions were compared
statistically using a Chi-square test, and the observed
distribution of the Chi-square statistic was used to evaluate
the significance of results empirically. This empirical ap-
proach was used because analysis by pooling introduces
additional sources of variance, beyond the expected sam-
pling variance, that are not normally distributed. A software
package to perform this statistical analysis was specifically
developed as part of the GAMES collaborative study (by
ES). The statistical methods are described in detail in the
accompanying paper from Setakis (2003).
The raw data from those markers with the most extreme
empirical p-values were reassessed and the best were taken
forward for a second analysis. In this second stage, we
employed the adapting factors established by Yeo et al.
(2003).
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We employed a two-stage approach in our search for
genes influencing susceptibility to MS. In the first stage, we
genotyped the 6000 microsatellite markers provided through
the Genetic Analysis of Multiple sclerosis in EuropeanS
(GAMES) collaborative in separately pooled DNA samples
from 188 cases and 188 controls. Usable allele image
patterns (AIPs) were obtained from 4661 markers. Seven-
ty-eight of these markers gave empirical p-values of < 0.01.
The raw AIPs from these 78 markers were re-inspected and
assessed for data quality, homogeneity and genotyping
errors. In the second stage, new AIPs were generated for
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analysed employing the adapting factors suggested by Yeo
et al. (2003). Ten markers retained empirical p-value < 0.01
in this refining analysis (see Table 1).4. Discussion
Given the importance of gene–environment interactions
in MS, it is possible that different genetic factors are
relevant to its pathogenesis in different populations. There-
fore, it may be helpful to consider various populations, and
those where the risk of the disease is less striking may be of
use precisely because the genetic risk factors are less
common, and easier to pinpoint.
We have performed a population-based whole-genome
screen for association with MS in the Portuguese population
using polymorphic microsatellites to identify chromosomal
regions containing genes potentially involved in suscepti-
bility to this disease. The study is dependant upon the
hypothesis that linkage disequilibrium will result in associa-
tions between neutral polymorphisms and functional risk-
conferring variants of relevant genes, so that certain marker
alleles will be over represented in patients compared with
the normal population (associated alleles).
In association studies, the sample size and the choice of
the control population are of crucial importance (Cardon
and Bell, 2001). Selection of a control group that really
represents the population, avoiding artefacts that may
either mask real effects or introduce population stratifica-
tion (and generate false positive results) is therefore
extremely important. It is also important to have a group
of patients that is large enough to provide the statistical
strength needed for detection of genes with subtle effects.
In this study, we individually paired every one of the 188
patients with a control individual from the same region of
the country (sharing a similar environment and genetic
background), of the same gender and with approximately
the same age (F 2 years).
In order to overcome the barrier provided by the large
number of genotypes needing to be completed, a DNA
pooling strategy was used, as proposed by Barcellos et al.
(1997) and previously employed by Sawcer et al. (2002) and
Shaw et al. (1998). This strategy allowed the genotyping of
thousands of markers for large case (n = 188) and control
(n = 188) groups, and then comparison of allele frequencies
in these groups, reflected in their respective allele image
patterns (AIP) (Daniels et al., 1998). Identification of differ-
ences in allele frequency distribution between cases and
controls was undertaken using a statistical program specif-
ically developed (by ES) for the purpose of the collaborative
study. We selected 34 markers from the screening phase that
were studied a second time during the refining stage. Of
these, 10 retained an empirical p-value of p < 0.01 after
refined analysis. Selection of markers was performed using
systematic criteria involving an evaluation of the dataquality (intensity of fluorescence) and the homogeneity of
results between duplicate electropherograms. We also con-
sidered the consistency between the original screening AIPs
and those observed in the refining phase. These markers
correspond to seven chromosomal regions: 4q, 5q, 6p, 7q,
10p, 11p and 11q. Of these, regions 5q, 6p have already
been referred as having a positive lod score in other whole
genome linkage studies (Sawcer et al., 1996; Haines et al.,
1996; Ebers et al., 1996), as well as the region on chromo-
some 7q identified in the Canadian study (Ebers et al.,
1996). More recently, whole genome LD studies suggested
regions that we could also identify, namely, chromosomal
regions 6p and 11p (Goedde et al., 2002) and regions 6p and
4q (Sawcer et al., 2002). Besides these five regions, we
suggest two additional ones (10p and11q), that might
represent new regions associated with MS: to our know-
ledge, these regions have not previously been referred as
relevant in MS. The replication of previous findings of
association with markers in the HLA region suggests that
this methodology is appropriate for the detection of loci
associated to MS.
Future work will involve individually genotyping the
best markers for association with MS in the individuals used
to construct the pool, replication of the results in a different
sample of MS patients, and refinement of the regions of
interest using additional markers.Acknowledgements
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